DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes

• Main Authors: Kizhakeyil, Atish, Zaini, Nurmahirah Binte Mohammed, Poh, Zhi Sheng, Wong, Brandon Han Siang, Loh, Xinpeng, Ng, Aik Seng, Low, Zun Siong, Prasannan, Praseetha, Gong, Chun, Tan, Michelle Guet Khim, Nagarajan, Chandramouli, Huang, Dachuan, Lu, Pang Wan, Lim, Jing Quan, Barrans, Sharon, Ong, Choon Kiat, Lim, Soon Thye, Chng, Wee Joo, Follows, George, Hodson, Daniel J, Du, Ming Qing, Goh, Yeow Tee, Tan, Suat Hoon, Grigoropoulos, Nicholas Francis, Verma, Navin Kumar
• Other Authors: DEAN'S OFFICE (MEDICINE)
• Format: Article
• Language: English
• Published: BMC 2022
• Subjects: Science & Technology; Life Sciences & Biomedicine; Biochemistry & Molecular Biology; Oncology; DDX3X mutation; Hematolymphoid malignancy; Prognosis; Tumour metastasis; Drug resistance; CYCLIN D1 EXPRESSION
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/228996
• Institution: National University of Singapore

10.1186/s12943-021-01437-0